Boston Scientific Corp (BSX)vsEquinor ASA ADR (EQNR)
BSX
Boston Scientific Corp
$53.93
-4.67%
HEALTHCARE · Cap: $84.08B
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $94.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 414% more annual revenue ($105.98B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 4.8%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
EQNR
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.7%
Fair Value
$46.22
Current Price
$53.93
$7.71 premium
Margin of Safety
+47.4%
Fair Value
$54.29
Current Price
$36.69
$17.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Large-cap with strong market position
Strong operational efficiency at 21.4%
Generating 2.1B in free cash flow
Areas to Watch
No major concerns identified
4.8% margin — thin
Weak financial health signals
Revenue declined 5.1%
Earnings declined 27.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : EQNR
The strongest argument for EQNR centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.03 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a mature stock while EQNR is a value play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.62 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (71/100 vs 51/100), backed by strong 17.3% margins and 11.6% revenue growth. EQNR offers better value entry with a 47.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?